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Abstract 9 
Recombinant protein sub-unit vaccines are formulated using protein antigens that have been 10 
synthesized in heterologous host cells. Several host cells are available for this purpose, 11 
ranging from Escherichia coli to mammalian cell-lines. This article highlights the benefits of 12 
using yeast as the recombinant host. The yeast species, Saccharomyces cerevisiae and 13 
Pichia pastoris, have been used to optimize the functional yields of potential antigens for the 14 
development of sub-unit vaccines against a wide range of diseases caused by bacteria and 15 
viruses. S. cerevisiae has also been used in the manufacture of eleven approved vaccines 16 
against hepatitis B virus and one against human papillomavirus; in both cases the 17 
recombinant protein forms highly-immunogenic virus-like particles. Advances in our 18 
understanding of how a yeast cell responds to the metabolic load of producing recombinant 19 
proteins will allow us to identify host strains that have improved yield properties and enable 20 
the synthesis of more challenging antigens that cannot be produced in other systems. 21 
Yeasts therefore have the potential to become important host organisms for the production 22 
of recombinant antigens that can be used in the manufacture of sub-unit vaccines or in new 23 
vaccine development. 24 
Recombinant protein sub-unit vaccines 25 
Most vaccines are based on formulations comprising either live, attenuated- or killed, 26 
inactivated-bacteria or viruses (1). Live, attenuated vaccines typically induce strong, long-27 
lasting immunity; however, while they are attenuated in their pathogenicity, concerns remain 28 
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about reversion to virulent wild-type strains that might cause disease in 29 
immunocompromised individuals (2). In contrast, killed, inactivated vaccines are non-30 
infectious (2), but are less effective in inducing protective immunity often requiring an 31 
adjuvant to stimulate antibody responses and effector T cell functions (3). The increasingly 32 
stringent demands of regulatory authorities such as the United States Food and Drug 33 
Administration (FDA), the European Medicines Agency (EMA) and the World Health 34 
Organization (WHO) require new vaccine compositions to be precisely specified. This makes 35 
developments using whole cell vaccines particularly challenging because they contain 36 
undefined molecules that originate from the source bacterium or the host cell used to 37 
produce the virus. 38 
In the last thirty years, there has been a trend towards developing sub-unit vaccine 39 
formulations that contain defined antigenic components together with a potent adjuvant (2). 40 
The antigen may be a polysaccharide, a nucleic acid or a protein. In the latter case, which is 41 
the focus of this article, the protein itself may be (i) a purified protein from the disease-42 
causing pathogen, (ii) a synthetic peptide or (iii) a recombinant protein that has been 43 
synthesized in one of many possible heterologous host cells ranging from Escherichia coli to 44 
mammalian cells (4). This ensures that the antigen has a well-defined composition, that 45 
there is effectively no risk of pathogenicity in its use and that antigen synthesis and 46 
purification can be scaled up in a cost-effective manner (5). Unfortunately, while many 47 
recombinant proteins exhibit immunogenicity in mice, they are not necessarily potent 48 
antigens in humans (even when administered with an effective adjuvant), as seen in the 49 
case of apical membrane antigen-1 (AMA-1), which is a leading blood-stage malaria vaccine 50 
antigen (6). However, some recombinant proteins form virus-like particles (VLP), which are 51 
multi-protein structures that mimic the organization and conformation of native viruses but 52 
without a viral genome (7). VLPs have been found to be more stable and considerably more 53 
immunogenic than purified protein antigens (7). Notably, the two currently-licensed 54 
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recombinant antigens manufactured in yeast are VLPs (Table 1).This review examines the 55 
role that yeast cells can play in further vaccine development. 56 
Recombinant gene expression technology was developed 41 years ago in E. coli (9), leading 57 
to the recombinant synthesis of the human hormones, somatostatin in 1977 (10) and insulin 58 
in 1979 (11). Today, the production of a wide range of recombinant biopharmaceuticals, 59 
including recombinant hormones, antibodies and vaccines, is a multi-billion dollar global 60 
business (12). More than 150 biopharmaceuticals have been approved by the FDA to date 61 
(13, 14), with approximately 20% of these recombinant proteins being produced in yeasts 62 
(the vast majority in S. cerevisiae), 30% in E. coli and 50% in mammalian cell-lines and 63 
hybridomas (5, 13, 15). Table 1 summarizes data for recombinant protein sub-unit vaccines 64 
that are either currently licensed for human use in the EU or the US or have previously been 65 
licensed but are now withdrawn. In contrast to the picture for biopharmaceuticals as a whole, 66 
it is notable that the majority of commercial vaccines use antigens that have been 67 
synthesized in microbes; 14 out of the 16 vaccines in Table 1 contain an antigen synthesized 68 
in either E. coli or S. cerevisiae although only two distinct antigens are actually synthesized 69 
in S. cerevisiae and two in E. coli. Recombinant hepatitis B surface antigen (HBsAg) 70 
synthesized in S. cerevisiae has been used in 11 different formulations (Table 1); the first of 71 
these was reported in 1982 (16) and was subsequently licensed in 1986 by the FDA for use 72 
in humans (2). Due to a lack of demand in the EU, GlaxoSmithKline Biologicals withdrew 73 
Tritanrix-HB® in 2009, while Aventis Pasteur MSD withdrew Primavax® in 2000 and 74 
Procomvax® in 2009, all of which contain recombinant HBsAg as part of multivalent vaccine 75 
formulations. A second antigen synthesized in S. cerevisiae is comprised of the 76 
major capsid protein, L1, from four human papillomavirus types (6, 11, 16 and 18) to 77 
generate the human papillomavirus vaccine, Gardasil®. In both cases these S. cerevisiae-78 
derived antigens form VLPs. An alternative VLP vaccine, Cervarix®, is formulated using 79 
recombinant major capsid protein, L1, from two human papillomavirus types (16 and 18) that 80 
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have been synthesized in insect cells; insect cells are also used in the manufacture of a 81 
second vaccine, Flublok® (Table 1). 82 
In 1998, a vaccine against Lyme disease, Lymerix®, was approved by the FDA.  Lymerix® 83 
incorporates recombinant surface lipoprotein, OspA, from Borrelia burgdorferi that is 84 
synthesized in E. coli (Table 1); however, the vaccine was withdrawn by the manufacturer in 85 
2002 due to a lack of demand in the US that followed extensive media coverage and 86 
ongoing litigation concerning adverse side effects (17). This was despite initial studies 87 
indicating that the Lymerix® vaccine was a cost-effective public health intervention for people 88 
at high risk of Lyme disease; its withdrawal precluded the design of more conclusive studies 89 
(18). Bexsero® was licensed in the EU in 2013 to protect against meningococcal meningitis 90 
and septicemia caused by meningococcal serogroup B (Table 1). It contains three antigens 91 
synthesized in E. coli in addition to an outer membrane vesicle from meningococcal strain 92 
MZ98/254. 93 
Recombinant antigen synthesis is possible in a range of host cells: the importance of 94 
Escherichia coli 95 
E. coli is typically the first choice of host cell for producing recombinant proteins in industrial 96 
and academic laboratories; it is a familiar laboratory organism, quick and inexpensive to 97 
culture and has the potential to generate high product yields (5). Unsurprisingly, it is 98 
therefore widely used in both commercial (for the manufacture of approximately 30% of 99 
protein biopharmaceuticals; (13, 15)) and research (in the synthesis of >70% of proteins (5)) 100 
laboratories. This situation is reflected by data in the published literature on recombinant 101 
antigen synthesis, which suggests a wide range of protein antigens have been produced in 102 
E. coli for use in the development of new recombinant protein sub-unit vaccines: on 8th 103 
October 2014, the PubMed Central database was searched for entries in any field containing 104 
“recombinant” and “vaccine” together with the name of the host cell; this returned 3,256 105 
articles for “coli”, 266 articles for “pastoris”, 288 articles for “cerevisiae”, 890 articles for 106 
“baculovirus” and 398 articles for CHO (or 107 articles for “Chinese hamster ovary”). While 107 
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this type of analysis can only be indicative, E. coli does appear to have an important role in 108 
research into recombinant antigens, in line with its wider use in recombinant protein 109 
production.   110 
Reports using E. coli as the host cell most often describe initial characterization of the 111 
recombinant antigen and demonstration of immunogenicity in mice, as illustrated by the 112 
following examples. Recombinant protective antigen (rPA83) has been characterized as a 113 
successful adjuvant-bound sub-unit vaccine against Bacillus anthracis, the causative agent 114 
of anthrax (19). Recombinant fraction 1 (Caf1) and V (LcrV) antigens induce protection 115 
against Yersinia pestis infection (the causative agent of bubonic and pneumonic plagues) 116 
one year post-vaccination (20). Flaccid paralytic disease or botulism is caused by neurotoxin 117 
F from Clostridium botulinum; the receptor-binding domain of neurotoxin F was synthesized 118 
as a fusion with or without maltose binding protein in E. coli and the purified protein 119 
protected mice against challenge with C. botulinum neurotoxin F ten months after 120 
vaccination (21). Helicobacter pylori infection causes stomach and duodenal ulcers in 121 
humans; the recombinant urease sub-units, UreA and UreB, induced an immunoprotective 122 
response in mice (22). Hospital-acquired infection such as pneumonia and sepsis are 123 
typically caused by Staphylococcus aureus. Data from studies in mice have suggested the 124 
potential to develop a protein sub-unit vaccine based on recombinant collagen binding 125 
bacterial adhesin fragment (CNA19) (23). A proof-of-principle leprosy vaccine development 126 
scheme recently demonstrated efficacy in mice using a 73f fusion protein (coded by aligning 127 
the individual gene sequences for ML2028, ML2346 and ML2044 from Mycobacterium 128 
leprae as a single product) (24). Two approaches to developing malaria vaccines 129 
(specifically disease caused by Plasmodium vivax) have examined recombinant domain II of 130 
AMA-1, which was demonstrated to be immunogenic in mice (25) and a soluble antigen 131 
called VMP001 based on the circumsporozoite protein, which was immunogenic in rhesus 132 
monkeys (26). A recombinant sub-unit vaccine formulated using a fusion protein between 133 
Ag85B and ESAT-6 was shown to be highly protective against Mycobacterium tuberculosis 134 
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(the causative agent of tuberculosis) in mice (27). Further examples include development of 135 
sub-unit vaccines to protect against dengue virus (28), hepatitis A virus (29), human 136 
immunodeficiency virus (30), human rotavirus (31), human respiratory syncytial virus (32), 137 
H1N1 influenza virus (33), Pseudomonas aeruginosa infection (34) and 138 
schistosomiasis (35). All these examples use E. coli as the recombinant host and illustrate 139 
the importance of this prokaryotic microbe as a tool in vaccine development. 140 
The use of eukaryotic hosts in recombinant protein sub-unit vaccine development: an 141 
emerging role for yeasts 142 
While E. coli has many benefits as a cell factory, producing a recombinant protein in a 143 
prokaryotic host cell can often result in inclusion body formation and/or low specific yields of 144 
a product lacking post-translational modification (36). This may be one reason for a general 145 
decline in the more recent use of E. coli as a host cell and the consequent emergence of 146 
several eukaryotic options (5).  147 
In principle, the use of mammalian cell-lines should overcome challenges associated with 148 
synthesizing eukaryotic proteins in prokaryotes, especially with recent advances in stable 149 
recombinant gene expression (37, 38). This is because rates of protein synthesis and folding 150 
are almost an order of magnitude faster in prokaryotes than they are in eukaryotes (39), 151 
eukaryotic codons are often inefficiently expressed in prokaryotes and authentic eukaryotic 152 
post-translational modifications cannot yet be achieved in E. coli (36). In support of this, 153 
Synagis®, which is used for passive immunization of infants to protect against respiratory 154 
syncytial virus, is formulated using a humanized monoclonal antibody (IgG11K; directed 155 
against an epitope of the viral F protein) synthesized in mouse myeloma cells (40). In clinical 156 
trials, a herpes simplex virus (HSV) vaccine, containing a truncated form of recombinant 157 
HSV-2 glycoprotein D from HSV-2 strain G that had been synthesized in Chinese hamster 158 
ovary cells, had efficacy in some women dependent on their serologic status, but no efficacy 159 
in men (41).  160 
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Insect cells have also been used for both commercial vaccine production (Cervarix® and 161 
Flublok®, Table 1) and in the synthesis of recombinant protein antigens for new vaccine 162 
development. For example, the receptor-binding domain of neurotoxin A (rBoNT/A-HC-6h) 163 
from Clostridium botulinum was synthesized in insect cells; purified rBoNT/A-HC-6h gave 164 
mice full protection against botulinum A toxin with a dose as low as 0.2μg (42). Merozoite 165 
surface protein 1 from P. falciparum (MSP-1, comprising 43 amino-terminal residues) was 166 
also synthesized in insect cells and demonstrated to be immunogenic in rabbits (43). Further 167 
examples include development of sub-unit vaccines, some incorporating glycoproteins that 168 
would not be possible to synthesize in E. coli: these include sub-unit vaccines against 169 
chandipura virus (44), hepatitis E virus (45), malaria (specifically disease caused by P. 170 
falciparum) (46), severe acute respiratory syndrome (SARS) virus (47) and West Nile virus 171 
(48). 172 
Plant cells have also been explored as recombinant hosts, with the added possibility of 173 
developing edible vaccines. The cholera toxin B subunit, immunoglobulins, α-interferon, VP1 174 
protein from foot-and-mouth disease virus and glycoprotein S from transmissible 175 
gastroenteritis virus have all been expressed in transgenic plants or by means of plant 176 
viruses (49, 50). Transgenic tobacco plants (Nicotiana tabacum) have also been used to 177 
synthesize a measles virus hemagglutinin (H) protein that was demonstrated to be 178 
immunogenic in mice (51).  179 
Eukaryotic microbes, especially S. cerevisiae and Pichia pastoris offer many of the benefits 180 
of higher eukaryotic host cells, whilst retaining the advantages of being microbial. Despite 181 
their propensity to hyper-glycosylate recombinant proteins (5), these two yeasts have many 182 
advantages: a wealth of molecular and genetic resources are available for both species (52, 183 
53), growth rates are an order of magnitude higher than mammalian cell-lines and they are 184 
cheap to culture (54). As discussed above, S. cerevisiae is already used in the manufacture 185 
of 12 out of the 16 approved vaccines shown in Table 1; these vaccines are considered safe 186 
and efficacious because they are noninfectious and highly immunogenic.  187 
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Table 2 shows examples from the literature suggesting that these advantages are becoming 188 
more widely known in academic research laboratories both for S. cerevisiae and P. pastoris; 189 
the latter yeast is a relative new-comer, having been first developed as a recombinant host 190 
system in 1985 (55). The PubMed Central database was searched for entries containing 191 
“sub-unit” and “vaccine” in any field, which returned 189 articles. This was augmented with 192 
searches for entries in any field containing “recombinant” and “vaccine” with the name of the 193 
host cell; this returned 266 articles for “pastoris” and 288 entries for “cerevisiae”. The articles 194 
were examined manually to identify the target disease, the recombinant antigen and the 195 
recombinant host cell. Many veterinary vaccines are in development, but only data for 196 
potential human recombinant sub-unit vaccines are shown. For S. cerevisiae, several 197 
vaccine candidates are based on inactivated whole yeast cells (56) or involve displaying the 198 
antigen on the surface of a yeast cell (57), but these are not included in Table 2; only studies 199 
using recombinant protein antigens are listed. What is immediately noticeable is the large 200 
proportion of very recent studies that have been published using yeast: for S. cerevisiae, 5 201 
out of 12 and for P. pastoris 17 out of 21 reports were published between 2010 and 2014. 202 
Designing improved recombinant antigen synthesis experiments 203 
In designing any new recombinant protein production strategy, optimization of the gene 204 
sequence should be considered so it is more likely to be stably expressed in the chosen 205 
recombinant host cell; there is an extensive literature on engineering stabilized proteins (58, 206 
59), while recent insights suggest that codon optimization (60) might aid functional 207 
expression (61). In addition, optimizing culture conditions and induction protocols is essential 208 
to increase recombinant protein yields; this has been demonstrated in cultures of both P. 209 
pastoris (62, 63) and E. coli (64). Successful implementation of a “Design of Experiments” 210 
approach to bioprocess optimization (65) enables the simultaneous investigation of multiple 211 
parameters and their interactions on the functional yield of a recombinant protein. In P. 212 
pastoris cultures, this approach was shown to increase the yield per cell by matching the 213 
induction feed profile to the cellular metabolism (66). In a separate study, pulsing P. pastoris 214 
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cells with an inducer (methanol) revealed the potential benefit of stress in increasing 215 
productivity (67). These advances are all easily applicable to recombinant antigen synthesis. 216 
S. cerevisiae is particularly amenable to studying the mechanistic basis of high-yielding 217 
recombinant protein production experiments using the tools of systems and synthetic biology 218 
(68). As stated in a recent review (5), identifying or engineering yeast strains with improved 219 
yield characteristics may either be targeted towards one particular pathway or may take a 220 
more global approach (69). Examples of the targeted approach include “humanizing” the 221 
yeast glycosylation (70) and sterol (71) pathways and modifying membrane phospholipid 222 
synthesis to proliferate intracellular membranes  (72). Studies taking a more global approach 223 
in both S. cerevisiae (73, 74) and P. pastoris (62, 75) have identified the importance of the 224 
unfolded protein response (the cellular stress response activated by the accumulation of 225 
unfolded or misfolded protein) and reduced translational activity in high yielding cultures. 226 
Such insights, which are not yet possible in higher eukaryotic systems, have been used to 227 
select specific yeast strains that can substantially improve recombinant protein yields 228 
compared to wild-type cells (76, 77). 229 
Conclusions 230 
E. coli is often the first host cell to be considered in the synthesis of a new recombinant 231 
protein, although the commercial production of approved sub-unit vaccines relies on S. 232 
cerevisiae and insect cells as well as E. coli (Table 1). Table 2 illustrates the use of yeast as 233 
a research tool in vaccine development. This is particularly notable for P. pastoris, which has 234 
become a popular host very recently. Using both prokaryotic and eukaryotic microbes makes 235 
practical sense, since working with bacteria and yeast require similar techniques, equipment 236 
and approaches. Yeasts should therefore be considered alongside E. coli in developing a 237 
strategy to produce recombinant protein sub-unit vaccines, especially those based on VLPs, 238 
or as a tool to screen novel antigens in new vaccine development. 239 
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Table 1.  Recombinant protein sub-unit vaccines approved for human use. Sub-unit vaccines containing a recombinant protein antigen 596 
that have been approved for human use in the United States of America (US) or the European Union (EU) are listed in order of the date on 597 
which they were approved. Data were retrieved on 28th May 2014 from the FDA 598 
(http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm093830.htm), EMA 599 
(http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landing_page.jsp&mid=) and the United Kingdom 600 
Department of Health (https://www.gov.uk/government/collections/immunisation-against-infectious-disease-the-green-book) websites. While 14 601 
out of 16 vaccine formulations contain antigens synthesized in microbes, only two distinct antigens are synthesized in Saccharomyces 602 







Protection conferred against Recombinant antigen 
 
Manufacturer Date approved 
Escherichia coli Lymerix® 
 
Borrelia burgdorferi (causative 
agent of Lyme disease in US) 
OspA lipoprotein  GlaxoSmithKline 
Biologicals 
 
1998 (US); vaccine 
withdrawn by 
GlaxoSmithKline 





(causative agent of 
meningococcal meningitis and 
septicemia) 
 
Factor H binding protein 
(fHbp), Neisserial adhesin A 
(NadA), Neisseria heparin 
binding antigen (NHBA) and 
Porin A (PorA) from 
meningococcal strain NZ 
98/254 
 






Hepatitis B virus Hepatitis B surface antigen 
(HBsAg) 
 




Hepatitis B virus and 
Haemophilus influenzae type B; 
causative agent of pneumonia or 
meningitis, especially in young 
children 
 
HBsAg Merck & Co Inc 1996 (US) 
 





(causative agent of 
diptheria), Clostridium tetani 
(causative agent of tetanus) and 
Bordetella pertussis (causative 
agent of whooping cough) 
 
Biologicals withdrawn by 
GlaxoSmithKline 
Biologicals in 2009 
 
 Twinrix® Hepatitis A and B viruses HBsAg GlaxoSmithKline 
Biologicals 
1996 (EU; adult 
vaccine); 1997 (EU; 
paediatric vaccine) 
 








Hepatitis B virus, C. diphtheria 
and C. tetani 
 
HBsAg Sanofi Pasteur 
MSD 
 
1998 (EU); vaccine 
withdrawn by Sanofi 





Hepatitis B virus and H. 
influenzae type B 
 
HBsAg Sanofi Pasteur 
MSD 
1999 (EU); vaccine 
withdrawn by Sanofi 
Pasteur MSD in 
2009 
 







Hepatitis B virus, C. 
diphtheria,  C. tetani, B. 


















Human papillomavirus Major capsid protein, L1, for 
human papillomavirus types 6, 
11, 16 and 18 
 








Insect cells Cervarix® 
 
Human papillomavirus Major capsid protein, L1, for 
human papillomavirus types 









Influenza virus Full-length hemagglutinin 
(influenza virus A strains, 
H1N1 and H3N2, and one 






Table 2.  Examples of recombinant protein antigens synthesized in yeast for use in developing human sub-unit vaccines. Antigens 605 
synthesized in S. cerevisiae or P. pastoris are listed alphabetically by the relevant disease. The PubMed Central database was searched for 606 
entries containing “sub-unit” and “vaccine” in any field, which returned 189 articles. This was augmented with searches for entries in any field 607 
containing “recombinant” and “vaccine” with the name of the host cell; this returned 266 articles for “pastoris” and 288 entries for “cerevisiae”. 608 
These articles were examined manually to identify the target disease, the antigen and the recombinant host cell. Many veterinary vaccines are 609 













Protective antigen component of the anthrax 
toxin complex, PA63 
Protection against infection was 







Tetanus toxin fragment C 
 
Protection against infection was 
demonstrated in mice 
(79) 
 Dengue virus Dengue envelope domain III (scEDIII) from 
all four serotypes 




 Hantavirus  
 





virus type 1 
 
Gag protein Spheroplasts released Gag virus-like 
particles extracellularly 
(82) 




N-terminally truncated form of outer-surface 
protein A (des-Cys1-OspA) 
Improved yields over synthesis in E. coli (83) 
 Malaria 
(Plasmodium spp) 
RTS,S that consists of sequences of the 
circumsporozoite protein and the hepatitis B 
surface antigen (HBsAg). RTS and S 
spontaneously assemble into mixed 
Vaccine is in phase 3 clinical trials; it 
induced protection in 56% of vaccinees 
(84) 
21 
polymeric particulate structures. These 
VLPsare each estimated to contain, on 






Sexual-stage surface antigens synthesized 
as a Pfs25-28 fusion protein 
Pfs25-28 elicits potent P. falciparum 





A particulate antigen called CSV-S,S based 
on the circumsporozoite (CSV) protein. It 
comprises CSV-S (a fusion protein between 
a soluble form of CSV and HBsAg) and free 
HBsAg co-expressed in yeast and self-
assembled into mixed VLPs 
 
The particulate antigen was immunogenic 




P1, the precursor for the structural proteins, 
and 3CD, the viral protease 
 
VLPs could be isolated (86) 
 Rabies virus 
 
Rabies virus surface glycoprotein  Protective following intramuscular 




 Rotavirus Structural proteins VP2, VP6 and VP7 
 









Recombinant 4 × Aβ15, four tandem repeats 
of amyloid β(1-15) interlinked by spacers 
Proposed as an alternative to previous 
human clinical trials of vaccination that 








Trans-sialidase containing the catalytic 
domain without the immunodominant SAPA 
(Shed Acute Phase Antigen) repeats 
The recombinant sub-unit vaccine was 
protective in mice 
(90) 
 Dengue virus Dengue virus type 2 envelope domain III 
(sEDIII-2) 
 





 Epstein-Barr virus 
 
EBNA1, the viral protein expressed in all 
EBV-associated malignancies; truncated 
EBNA1 (E1ΔGA, codons 390-641) was 
expressed as a secretory protein with an N-
terminal polyhistidine tag 
 
Recombinant  E1ΔGA was demonstrated 
to be immunogenic in mice 
(92) 





VP1, one of the major immunogenic capsid 
proteins of human enterovirus 71 
Recombinant VP1 protein was 
immunogenic in mice 
(93) 
 Helicobacter pylori 
infection 
 
Alkyl hydroperoxide reductase (AhpC) Protection against infection was 
demonstrated in mice 
 
(94) 
 Hepatitis B virus Hepatitis B surface antigen (HBsAg) 
 
Production and purification of  VLPs that 




 Hepatitis C virus 
 
E1E2 protein, which consists of E1 residues 
187-346 and E2 residues 381-699 
 
E1E2 protein was immunogenic in rabbits 
 
(96) 




N. americanus glutathione S-transferase 
(Na-GST-1) 
Scale-up of production was demonstrated 





virus type 1 
 






Major capsid protein, L1, for human 
papillomavirus type 16  
 




9 kDa recombinant protein corresponding to 
the extracellular domain of a unique S. 
mansoni tetraspanin 






 Influenza virus A 
(avian origin) 
Recombinant neuraminidase (rNA) antigen The recombinant antigen induced an 








H1N1 hemagglutinin (HA) protein 
 
Recombinant production of endotoxin-free 
H1N1 HA was demonstrated 
(102) 
 Japanese 
encephalitis virus  
 
Viral envelope protein (E) Immunogenicity and protective efficacy 





Leptospiral immunoglobulin-like (Lig) protein 
LigANI and the immunodominant lipoprotein 
LipL32 
Recombinant proteins produced in E. coli 
have demonstrated variable results. 
LigANI and LipL32 from P. pastoris 
retained the antigenic characteristics of 







Circumsporozoite protein (CS) multimerized 
by fusion to the measles virus nucleoprotein 
(N) known to auto-assemble in yeast in 
large-size ribonucleoprotein rods (RNPs) 
 
Subcutaneous immunization of mice with 
heat-inactivated whole 
P. pastoris expressing N-CS RNPs 
provided significant reduction of 
parasitemia after intradermal challenge 







Merozoite surface protein 1 (MSP-1), 
comprising 43 N-terminal MSP-1 residues 
(the 19 residue MSP-1 signal sequence, 
which is removed by processing in 
baculovirus, plus 24 residues from N-
terminal block 1) and the adjacent 16 amino 
acid residues, and other variants 
 






Apical membrane antigen-1 AMA-1 
 
Secreted recombinant forms of  AMA-1 







Capsid protein (strain VA387, genogroup 
II.4) 
 
Oral administration of yeast extracts 
without an adjuvant stimulated an 







Chimeric surface antigen 1 and 2 (SAG1/2) Vaccinated mice were significantly 
protected against lethal challenge with 
live T. gondii 
 
(104) 
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